公告称，收入增加主要是由于奥布替尼销量增长强劲及来自Prolium的许可收益。奥布替尼的收益由截 至2024年6月30日止6个月的4.17亿元增加52.8%至截至2025年6月30日止6个月的 6.37亿元，是由于覆盖 范围拓宽及治疗患者增加所致。 智通财经APP讯，诺诚健华(09969)发布截至2025年6月30日止6个月中期业绩，该集团取得收益人民币 7.31亿元(单位下同)，同比增加74.26%;期内经调整亏损1550.4万元，同比减少93.62%;母公司拥有人应占 亏损3009.1万元，同比减少88.51%;每股亏损0.02元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 截至2025年6月30日止六個月中期業績公告 諾誠健華醫藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）欣然公佈，本集團截至2025年6月30日止六個月（「報告期」） 之未經審核綜合業績連同截至2024年6月30日止六個月之比較數字。 在本公告內，「我們」及「我們的」均指本公司，如文義另有所指，則指本集團。 本公告所載若干金額及百分比數字已約整或已四捨五入至小數點後一位或兩 位數（如適用）。任何表格、圖表或其他地方所示總額與所列數額總和如有任何 差異乃因四捨五入所致。除另有界定外，本公告所使用詞彙與招股章程已界定 者具有相同涵義。 – 1 – | 財務摘要 | | | | --- | --- | --- | ...

Market Overview - The market experienced fluctuations with the three major indices slightly declining, with the Shanghai Composite Index down 0.02%, the Shenzhen Component Index down 0.12%, and the ChiNext Index down 0.17% [1] - Over 2900 stocks rose in the market, with a total trading volume of 2.59 trillion yuan, a decrease of 175.8 billion yuan from the previous trading day, marking the fifth consecutive day of trading volume exceeding 2 trillion yuan [1] Sector Performance - Sectors such as liquor, Huawei HiSilicon, CPO, and humanoid robots saw significant gains, while insurance, military industry, securities, and gaming sectors experienced declines [1] - The liquor sector is noted for its low market expectations and valuations, with leading companies exhibiting strong dividend characteristics, making it a long-term investment opportunity [12] Stock Movements - The stock of Cambrian Technology reached a peak of 1001.1 yuan but closed at 933.98 yuan, indicating a significant pullback after hitting a milestone [9] - High-position stocks collectively retreated, with notable declines in companies like Sino Medical and Shenghong Technology, while some stocks in the pharmaceutical sector showed mixed performance [11][13] Market Sentiment and Trends - The market is currently at a critical juncture, with high trading volumes indicating a potentially overheated market environment, particularly following the significant trading volume of 2.8 trillion yuan on August 18 [8] - Analysts suggest that if market heat can be contained, there will be healthy upward performance; however, sustained high levels of activity may increase volatility risks [8] Future Outlook - The market is in a strong upward trend, with the potential to attract external funds, as deposit growth has not significantly declined [14] - Current strategies favor trend-following approaches, with a focus on maintaining positions rather than making predictions [14]

云南锗业午后直线拉升，盘中一度涨停。 | 分时 多日 1分 5分 15分 30分 60分 日 周 月 更多 | | | | | | F9 盘前盘后 叠加 九转 画线 工具 谷 | | 云南墙业 | | 002428 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 25.82 | | 002428[云南诸业] 14:17 价 25.82 涨跌 2.35(10.01%) 均价 24.20 成交量 6.31万 成交金额 1.53亿 | | | | 2025/08/19 | | | | +2.35 +10.01% | | | | | | | | Wind 人气榜 第995名 | | | CNY 14:17:36 交易中 | 土区 2 2 2 日 日 1 2 日 1 2 日 1 2 2 1 日 1 2 2 1 1 2 | | 24.65 | | | | | | | | 중 다 | 100.00% 委并 | 437465 | | | | | | | | | | 英五 | | | | | | | | | | | | 英四 | | ...

Group 1 - The A-share market has seen a decline in several biopharmaceutical stocks, with notable drops including Nanmo Bio down 9%, Shanghai Yizhong down over 7%, and Nuocheng Jianhua down over 5% [1] - Other companies experiencing declines include Yangguang Nuohuo and Guangshengtang down over 4%, and Haichuang Pharmaceutical, Baicheng Pharmaceutical, Yaokang Bio, and Qianyan Bio down over 3% [1] Group 2 - Specific stock performance includes: - Nanmo Bio (688265) down 9.06% with a market cap of 5.027 billion and a year-to-date increase of 178.89% - Shanghai Yizhong (688091) down 7.23% with a market cap of 15.7 billion and a year-to-date increase of 89.98% - Nuocheng Jianhua (688428) down 5.25% with a market cap of 56 billion and a year-to-date increase of 158.55% - Yangguang Nuohuo (688621) down 4.57% with a market cap of 8.727 billion and a year-to-date increase of 107.29% - Guangshengtang (300436) down 4.26% with a market cap of 26.3 billion and a year-to-date increase of 404.68% [2]

Group 1 - A-share market sees weakness in certain biopharmaceutical stocks, with notable declines in several companies [1] - Nanmo Bio falls by 9%, while Shanghai Yizhong drops over 7% [1] - Nocare Health declines by over 5%, and Sunshine Nuohe and Guangshengtang both decrease by over 4% [1] - Haichuang Pharmaceutical, Baicheng Pharmaceutical, Yaokang Bio, and Qianyan Bio all experience declines of over 3% [1]

医药股盘中分化，广生堂跳水一度跌近10%，诺诚健华、南模生物、上海谊众、创新医疗等纷纷大幅走 低。 ...

智通财经APP获悉，2025年8月19日，港股上市公司投资日志如下： 类别 公司 业绩公布日 股东大会召开日 新股活动 双登股份 (招股中) 易鑫集团 诺诚健华 小米集团-W 小鹏汽车-W WMCH GLOBAL 贸易通 华润啤酒 南华金融 民生教育 金力永磁 NATIONAL ELEC H 米高集团 中国智能科技 嘉艺控股 进升集团控股 中显智能齐家控股 医思健康 沪港联合 奥克斯国际 兆邦基生活 理文化工 （除净日） 宏利金融-S （除净日） 理文造纸 （除净日） 俊盟国际 （除净日） 互太纺织 （除净日） 美丽田园医疗健康 （除净日） 鼎石资本 （除权日） 分红派息 股本增发 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Ping An Medical Health Mixed C fund, which has shown significant growth in recent months and year-to-date [1] - As of August 18, 2025, the latest net value of the fund is 2.9725 yuan, reflecting a growth of 1.24% [1] - The fund's one-month return is 2.68%, six-month return is 81.82%, and year-to-date return is 92.00%, with respective rankings of 1127 out of 1212, 8 out of 1181, and 9 out of 1179 [1] Group 2 - The top ten stock holdings of the Ping An Medical Health Mixed C fund account for a total of 75.91%, with the largest holding being Ginkgo BioWorks at 10.55% [1] - Other significant holdings include Innovent Biologics (9.08%), CanSino Biologics (8.97%), and BeiGene (7.58%) [1] - The fund was established on November 28, 2023, and as of June 30, 2025, it has a total scale of 1.216 billion yuan, managed by fund manager Zhou Sicong [1][2]

Group 1 - A-share indices have been rising, leading to a significant increase in the net value of public funds, with over 2000 funds reaching historical highs from August 11 to August 15 [1] - More than 200 funds have surpassed a net value of 2 yuan, marking the end of the "1 yuan" era for many funds [2] - The number of funds entering the "10 yuan" tier has increased, with notable funds like Huashang Advantage Industry reaching a net value above 10 yuan for the first time [2] Group 2 - Innovative drug-themed funds have shown outstanding performance, with nine out of the top ten funds this year primarily investing in the innovative drug sector [3] - The top three performing funds in the innovative drug space have return rates exceeding 120% this year [3] - Common holdings among these funds include companies like Kelun Biotech and Innovent Biologics, indicating a trend in investment focus [3] Group 3 - Market sentiment has improved significantly, with trading volumes exceeding 20 trillion yuan over three consecutive days [4] - Institutions express optimism about future market performance, particularly in technology, pharmaceuticals, and finance sectors [4] - Morgan Stanley highlights that A-shares remain undervalued compared to overseas markets, with significant growth potential in technology, manufacturing, and new consumption sectors [5] Group 4 - Fund managers suggest focusing on "big technology + big finance" as a strategic investment direction, emphasizing AI hardware, military, and non-bank financial sectors [4][5] - The positive changes in market liquidity are expected to lead to a virtuous cycle of capital inflow and market growth [5]